185 related articles for article (PubMed ID: 28859739)
1. Brodalumab (Siliq
Gupta AK; Versteeg SV; Abramovits W; Vincent KD
Skinmed; 2017; 15(4):281-285. PubMed ID: 28859739
[No Abstract] [Full Text] [Related]
2. Brodalumab versus ustekinumab in psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
[No Abstract] [Full Text] [Related]
3. Brodalumab: A Review of Safety.
Rusta-Sallehy S; Gooderham M; Papp K
Skin Therapy Lett; 2018 Mar; 23(2):1-3. PubMed ID: 29562088
[TBL] [Abstract][Full Text] [Related]
4. A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
Tong Y; Peranteau AJ; Nawas Z; Tyring SK
Skin Therapy Lett; 2017 Jan; 22(1):1-6. PubMed ID: 28122092
[TBL] [Abstract][Full Text] [Related]
5. Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
Med Lett Drugs Ther; 2017 Jul; 59(1525):118-119. PubMed ID: 28699932
[No Abstract] [Full Text] [Related]
6. Anti-IL-23 Phase II Data for Psoriasis: A Review.
Beroukhim K; Danesh MJ; Nguyen C; Austin A; Koo J; Levin E
J Drugs Dermatol; 2015 Oct; 14(10):1093-6. PubMed ID: 26461819
[TBL] [Abstract][Full Text] [Related]
7. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
8. [Ustekinumab].
Ortonne JP
Ann Dermatol Venereol; 2011 Dec; 138(12):848-50. PubMed ID: 22137626
[No Abstract] [Full Text] [Related]
9. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
Campa M; Menter A
Expert Opin Investig Drugs; 2016 Nov; 25(11):1337-1344. PubMed ID: 27687859
[TBL] [Abstract][Full Text] [Related]
10. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
[TBL] [Abstract][Full Text] [Related]
11. [Infliximab].
Goujon C; Bachelez H
Ann Dermatol Venereol; 2011 Dec; 138(12):839-41. PubMed ID: 22137623
[No Abstract] [Full Text] [Related]
12. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
Roman M; Chiu MW
Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
[TBL] [Abstract][Full Text] [Related]
13. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
[No Abstract] [Full Text] [Related]
14. Briakinumab for the treatment of plaque psoriasis.
Traczewski P; Rudnicka L
BioDrugs; 2012 Feb; 26(1):9-20. PubMed ID: 22077474
[TBL] [Abstract][Full Text] [Related]
15. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
17. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
[TBL] [Abstract][Full Text] [Related]
18. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience.
Becatti M; Urban ML; Taurisano G; Mannucci A; Barygina V; Pescitelli L; Prignano F; Silvestri E; Taddei N; Lotti T; Fiorillo C; Emmi G
Dermatol Ther; 2018 Sep; 31(5):e12675. PubMed ID: 30133998
[No Abstract] [Full Text] [Related]
20. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.
Amin M; Darji K; No DJ; Wu JJ
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1627-1632. PubMed ID: 28667777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
